268 related articles for article (PubMed ID: 29705869)
1. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
Yee KL; McCrea J; Panebianco D; Liu W; Lewis N; Cabalu T; Ramael S; Wrishko RE
Clin Drug Investig; 2018 Jul; 38(7):631-638. PubMed ID: 29705869
[TBL] [Abstract][Full Text] [Related]
2. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.
Uemura N; McCrea J; Sun H; Donikyan M; Zammit G; Liu R; Louridas B; Marsilio S; Lines C; Troyer MD; Wagner J
J Clin Pharmacol; 2015 Oct; 55(10):1093-100. PubMed ID: 25903940
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
[TBL] [Abstract][Full Text] [Related]
4. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.
Sun H; Yee KL; Gill S; Liu W; Li X; Panebianco D; Mangin E; Morrison D; McCrea J; Wagner JA; Troyer MD
J Psychopharmacol; 2015 Nov; 29(11):1159-69. PubMed ID: 26464455
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
[TBL] [Abstract][Full Text] [Related]
6. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning.
Bland H; Li X; Mangin E; Yee KL; Lines C; Herring WJ; Gillespie G
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):414-420. PubMed ID: 34181362
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
8. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study.
Masuyama T; Sanui M; Yoshida N; Iizuka Y; Ogi K; Yagihashi S; Nagatomo K; Sasabuchi Y; Lefor AK
Psychogeriatrics; 2018 May; 18(3):209-215. PubMed ID: 29423967
[TBL] [Abstract][Full Text] [Related]
9. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
Vermeeren A; Sun H; Vuurman EF; Jongen S; Van Leeuwen CJ; Van Oers AC; Palcza J; Li X; Laethem T; Heirman I; Bautmans A; Troyer MD; Wrishko R; McCrea J
Sleep; 2015 Nov; 38(11):1803-13. PubMed ID: 26039969
[TBL] [Abstract][Full Text] [Related]
10. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
11. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
[TBL] [Abstract][Full Text] [Related]
12. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
13. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
[TBL] [Abstract][Full Text] [Related]
14. Suvorexant: scientifically interesting, utility uncertain.
Keks NA; Hope J; Keogh S
Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
16. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
[TBL] [Abstract][Full Text] [Related]
17. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
18. Preventive Effects of Suvorexant on Delirium: A Randomized Placebo-Controlled Trial.
Hatta K; Kishi Y; Wada K; Takeuchi T; Ito S; Kurata A; Murakami K; Sugita M; Usui C; Nakamura H;
J Clin Psychiatry; 2017; 78(8):e970-e979. PubMed ID: 28767209
[TBL] [Abstract][Full Text] [Related]
19. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
20. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
